Abaloparatide Brand Name
TYMLOS
What is Abaloparatide
Abaloparatide is an analog of human parathyroid hormone related peptide, PTHrP (1-34).
It is used for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
Similar to teriparatide, the abaloparatide label contains a boxed warning regarding the risk of osteosarcoma and the drug is not recommended for use in patients at risk for osteosarcoma.
In addition, cumulative use of abaloparatide and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patient’s lifetime is not recommended.
Abaloparatide was approved by the FDA in April 2017.
Indications
- osteoporosis
For the treatment of postmenopausal women with osteoporosis at high risk for fracture
Side Effects
- abdominal pain
- antibody formation
- dizziness
- fatigue
- headache
- hypercalcemia
- hypercalciuria
- hyperuricemia
- injection site reaction
- nausea
- nephrolithiasis
- new primary malignancy
- orthostatic hypotension
- osteogenic sarcoma
- palpitations
- sinus tachycardia
- vertigo
Monitoring Parameters
- serum calcium
- serum uric acid
Contraindications
- breast-feeding
- children
- hypercalcemia
- hypercalciuria
- hyperparathyroidism
- infants
- nephrolithiasis
- new primary malignancy
- orthostatic hypotension
- osteogenic sarcoma
- pregnancy
- radiation therapy
- renal failure
- renal impairment
Interactions
There are no drug interactions associated with Abaloparatide products.
